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Abstract
Introduction: The cause of the metabolic syndrome 
(MS) is incompletely understood but represents a 
complex interaction between genetic, environmental, 
and metabolic factors, clearly including diet, and level of 
physical activity. The prevalence of MS is continuously 
increasing in the general population. Recently it has 
been found that MS is also common in renal transplant 
recipients (RTRs). The aim of this study was to determine 
the prevalence and characteristics of MS  in a group of 
Libyan renal transplant recipients, using two different 
diagnostic criteria.
Methods: This study was conducted at the Nephrology 
Department of the National Heart Center, Tripoli, 
Libya. We determined the prevalence of MS in a group 
of renal transplant recipients using both the National 
Cholesterol Education Program Adult Treatment Panel 
III (NCEP-ATP III) criteria and the International Diabetes 
Federation (IDF) criteria. All patients were more than six 
months post transplantation. Patients with Pre-transplant 
diabetes mellitus were excluded from the analysis.  
Results: By using the NCEP-ATP III criteria 26 out of 91 
patients (28.6%) had the metabolic syndrome. MS  was 
commoner in females than males, affecting 12 out of 35 
females (34.3%) and 14 out of 56 males (25%). Using 
the IDF criteria the metabolic syndrome was diagnosed 
in 23 patients (25.3%). In this group of patients the most 
common component of the metabolic syndrome was 
high blood pressure and the least common was impaired 
glucose tolerance and diabetes. 
Conclusions: The prevalence of MS in our renal 
transplant patients is high, affecting females more than 
males.
Key words: International Diabetes Federation; Metabolic 
Syndrome; NCEP-ATP III; Renal Transplant Recipients
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Introduction
The Metabolic syndrome (MS) was originally described 
in 1988 as «syndrome X» by Reaven et al [1]. The Adult 
Treatment Panel III (ATP III) of the National Cholesterol 
Education Program (NCEP) [2] defines MS clinically 
by the presence of any three of the following five 
traits: abdominal obesity, elevated fasting glucose level 
(reflecting insulin resistance), elevated blood pressure 
(BP), elevated serum triglyceride level and low HDL 
cholesterol level. The International Diabetes Federation 
(IDF) criteria define MS by the presence of central 
obesity plus any two of the remaining criteria used in the 
ATPIII/NECP classification.
The cause of the metabolic syndrome is not completely 
understood but it represents a complex interaction 
between genetic, environmental, and metabolic factors, 
clearly including diet [3, 4] and level of physical activity 
[4, 5]. The prevalence of MS is continuously increasing 
in the general population [6]. Recently, it has been found 
that MS is also common in renal transplant recipients 
(RTRs) [7]. The Metabolic syndrome is associated with 
a two-fold increase in the risk for cardiovascular disease 
(CVD), CVD mortality, myocardial infarction, and 
stroke as well as a 1.5 fold increase in the risk of all-cause 
mortality [8, 9]. Renal transplant recipients (RTRs) have 
about four-times higher mortality after the first year 
compared with the general population [10]. CVD events 
represent the single most frequent cause of death in 
RTRs accounting for 35-50% of all-cause mortality and 
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they occur at least twice as often as in the background 
population [10-14].
A community based population study demonstrated that 
established CVD risk factors are associated with the 
development of new onset kidney disease [15]. Recently, 
both obesity and MS have been suggested to participate 
in the pathogenesis of renal disease [16] as well as 
chronic allograft nephropathy [7]. Another study showed 
that MS is a prominent risk factor for new-onset diabetes 
mellitus , chronic graft dysfunction, graft loss and patient 
death in RTRs [17]. These reports suggest that MS may 
be a risk factor for renal dysfunction and CVD not only 
in the general population but also in RTRs. The present 
study investigated the prevalence of MS in  a group of 
Libyan renal transplant recipients using the National 
Cholesterol Education Program Adult Treatment Panel 
III (NCEP-ATP III) and the International Diabetic 
Federation (IDF) criteria.
Methods
This study was conducted at the Nephrology Department 
of the National Heart Center, Tripoli, Libya. We included 
a total of 91 live related and non-related renal transplant 
recipients, all of whom were more than 6 months post 
transplantation. Patients with pre-transplant diabetes 
mellitus were excluded. Patients were receiving 
combination therapy with cyclosporine or tacrolimus, 
azathioprine or mycophenolate mofetil along with 
prednisolone at a dose of 0.07 to 0.1/mg/kg/day. All 
patients gave informed consent for participation in the 
study.
After 10-12 hours over night fast, blood samples were 
taken for determination of glucose, creatinine, triglyceride 
(TG), and high density lipoprotein (HDL) cholesterol by 
auto-analyzer (Cobas Integra 400 plus, Roche). Waist 
circumference was determined by using a non-stretchable 
measuring tape midway between the iliac crest and costal 
margin. 
According to NCEP ATP III criteria, the diagnosis of MS 
was made when three or more of the following criteria 
were fulfilled [18]: (i) serum TG level ≥ 150 mg/dl or 
specific treatment for this lipid abnormality, (ii) serum 
HDL cholesterol level < 40 mg/dl in men or < 50 mg/dl 
in women or specific treatment for this lipid abnormality, 
(iii) systolic blood pressure (SBP) ≥ 130 mmHg and/or 
diastolic blood pressure (DBP) ≥ 85 mmHg or use of 
antihypertensive medications, (iv) fasting plasma glucose 
level  >100 mg/dl or use of anti-diabetic medications, and 
(v) waist girth > 102 cm for men and > 88 cm for women. 
According to the International Diabetes Federation criteria 
[19], subjects with central obesity (defined as waist girth 
> 102 cm for men and > 88 cm for women) plus any two 
of the remaining four criteria were considered to have 
MS. 
The statistical Package for Social Sciences version 14 
for windows (SPSS Inc, Chicago, IL, US) was used for 
statistical analysis. Continuous data were expressed as 
means and standard deviations and categorical data as 
percentages. Continuous variables were compared by 
the independent t-test and categorical data by the Chi 
squared test. P value < 0.05 was considered statistically 
significant. 
Results
By using the NCEP-ATPIII criteria  26 of 91 patients 
(28.6%) had the metabolic syndrome. It was diagnosed 
in 12 out of 35 females (34.3%) and 14 out of 56 males 
(25%) indicating female predominance. The mean age of 
the  MS group was more than that of the non-MS group 
(46 ± 12 versus 40 ± 11years respectively; P = 0.03). Mean 
serum creatinine level was not different between the two 
groups (1.2 ± 0.5 versus 1.4 ± 0.8 mg/dl respectively; P 
= 0.04). 
By using IDF criteria, MS was diagnosed in 23 patients 
(25.3%), the prevalence was 31.4% in the females and 
21.4% in the males. Table-1 shows the prevalence of 
different components of the metabolic syndrome. The 
most prevalent component of the metabolic syndrome 
was elevated blood pressure and the least common was 
elevated fasting plasma glucose level. 
Discussion
Among the numerous current definitions of the  MS 
(World Health Organization, European Group for the 
Study of Insulin Resistance, American Association 
of Clinical Endocrinologists, and the IDF), the one 
proposed by the NCEP-ATPIII is most widely Used [2]. 
The criteria were modified in 2005 by the American 
Heart Association (AHA) and the National Heart, Lung 
and Blood Institute (NHBI) [20].
In the general population the prevalence of MS differs 
widely among ethnic groups and according to diagnostic 
criteria used [21-23]. De Varies et al showed that the 
prevalence of MS among renal transplant patients using 
the original NCEP ATP III criteria was 63% [7]. The 
Australian study on renal transplant patients using the 
same criteria revealed 50% prevalence of MS among 
these patients [24]. Porrini et al found that 37.7% of 
Spanish RTRs had MS by using the modified criteria 
[17]. These reports suggested that MS is more prevalent 
in renal transplant recipients as compared to the general 
population with ethnic variation. 
Obesity is common in renal transplant recipients and is 
associated with worsening cardiovascular parameters and 
proteinuria progression [24]. The metabolic syndrome is 
a prominent risk factor for new-onset diabetes mellitus 
[17]. It has been reported that MS is a risk factor for 
renal dysfunction in the general population [15] and a 
prominent risk factor for chronic graft dysfunction [7, 17, 
25, 26]. Our study did not show significant difference 
in serum creatinine levels between MS and non-MS 
patients.
Our results showed that the prevalence of MS differed 
according to the criteria used; it is slightly lower by 
using the IDF than the NCEP ATP III criteria (25.3% 
versus 28.6%). By using the NCEP ATP III criteria the 
prevalence of MS in our patients is consistent with the 
results of Ozdemir et al [25]. Some studies reported 
higher prevalence [7, 27, 28] while other investigators 
showed less prevalence [26, 29, 30] compared to our 
results. This may be due to ethnic variations. MS in this 
study was more prevalent in females compared to males, 
which is consistent with the results shown by the Chinese 
study [31] and by Elahi et al [27]. In contrast, the results 
of the Japanese study [30] showed that the prevalence 
of MS was more common in males than females. The 
most common component of metabolic syndrome was 
high blood pressure which is similar to the results of the 
Chinese study [31] and Elahi et al [27]. The least common 
component was impaired fasting glucose and diabetes 
mellitus which is consistent with the results shown by 
Elahi et al [27]. On other hand, the Chinese study results 
[31] showed that low high density lipoprotein-cholesterol 
level was the least common component. 
Conclusion
The prevalence of MS in our renal transplant patients is 
high, affecting females more than males.
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                                                          Total (n = 91)                                          Men (n = 56)                        Women (n = 35)
Central obesity                                 46                                                       36                                         63
Hypertension                                58                                                    60                                         54
High TG                                                44                                                    48                                         37
Low HDL-Cholesterol                          33                                                    25                                         46
Hyperglycemia                               29                                                    34                                         23
MS (NCEP-ATP III criteria)               28.6                                                    25                                         34.2 
MS (IDF criteria)                               25.3                                                   30.4                                               21.4 
Table 1: Prevalence of different components of the metabolic syndrome in the study population
TG: triglyceride; HDL: high density lipoprotein; MS: metabolic syndrome; NCEP-ATP: National Cholesterol Education Program Adult Treatment 
Panel III; IDF: International Diabetes Federation
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they occur at least twice as often as in the background 
population [10-14].
A community based population study demonstrated that 
established CVD risk factors are associated with the 
development of new onset kidney disease [15]. Recently, 
both obesity and MS have been suggested to participate 
in the pathogenesis of renal disease [16] as well as 
chronic allograft nephropathy [7]. Another study showed 
that MS is a prominent risk factor for new-onset diabetes 
mellitus , chronic graft dysfunction, graft loss and patient 
death in RTRs [17]. These reports suggest that MS may 
be a risk factor for renal dysfunction and CVD not only 
in the general population but also in RTRs. The present 
study investigated the prevalence of MS in  a group of 
Libyan renal transplant recipients using the National 
Cholesterol Education Program Adult Treatment Panel 
III (NCEP-ATP III) and the International Diabetic 
Federation (IDF) criteria.
Methods
This study was conducted at the Nephrology Department 
of the National Heart Center, Tripoli, Libya. We included 
a total of 91 live related and non-related renal transplant 
recipients, all of whom were more than 6 months post 
transplantation. Patients with pre-transplant diabetes 
mellitus were excluded. Patients were receiving 
combination therapy with cyclosporine or tacrolimus, 
azathioprine or mycophenolate mofetil along with 
prednisolone at a dose of 0.07 to 0.1/mg/kg/day. All 
patients gave informed consent for participation in the 
study.
After 10-12 hours over night fast, blood samples were 
taken for determination of glucose, creatinine, triglyceride 
(TG), and high density lipoprotein (HDL) cholesterol by 
auto-analyzer (Cobas Integra 400 plus, Roche). Waist 
circumference was determined by using a non-stretchable 
measuring tape midway between the iliac crest and costal 
margin. 
According to NCEP ATP III criteria, the diagnosis of MS 
was made when three or more of the following criteria 
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specific treatment for this lipid abnormality, (ii) serum 
HDL cholesterol level < 40 mg/dl in men or < 50 mg/dl 
in women or specific treatment for this lipid abnormality, 
(iii) systolic blood pressure (SBP) ≥ 130 mmHg and/or 
diastolic blood pressure (DBP) ≥ 85 mmHg or use of 
antihypertensive medications, (iv) fasting plasma glucose 
level  >100 mg/dl or use of anti-diabetic medications, and 
(v) waist girth > 102 cm for men and > 88 cm for women. 
According to the International Diabetes Federation criteria 
[19], subjects with central obesity (defined as waist girth 
> 102 cm for men and > 88 cm for women) plus any two 
of the remaining four criteria were considered to have 
MS. 
The statistical Package for Social Sciences version 14 
for windows (SPSS Inc, Chicago, IL, US) was used for 
statistical analysis. Continuous data were expressed as 
means and standard deviations and categorical data as 
percentages. Continuous variables were compared by 
the independent t-test and categorical data by the Chi 
squared test. P value < 0.05 was considered statistically 
significant. 
Results
By using the NCEP-ATPIII criteria  26 of 91 patients 
(28.6%) had the metabolic syndrome. It was diagnosed 
in 12 out of 35 females (34.3%) and 14 out of 56 males 
(25%) indicating female predominance. The mean age of 
the  MS group was more than that of the non-MS group 
(46 ± 12 versus 40 ± 11years respectively; P = 0.03). Mean 
serum creatinine level was not different between the two 
groups (1.2 ± 0.5 versus 1.4 ± 0.8 mg/dl respectively; P 
= 0.04). 
By using IDF criteria, MS was diagnosed in 23 patients 
(25.3%), the prevalence was 31.4% in the females and 
21.4% in the males. Table-1 shows the prevalence of 
different components of the metabolic syndrome. The 
most prevalent component of the metabolic syndrome 
was elevated blood pressure and the least common was 
elevated fasting plasma glucose level. 
Discussion
Among the numerous current definitions of the  MS 
(World Health Organization, European Group for the 
Study of Insulin Resistance, American Association 
of Clinical Endocrinologists, and the IDF), the one 
proposed by the NCEP-ATPIII is most widely Used [2]. 
The criteria were modified in 2005 by the American 
Heart Association (AHA) and the National Heart, Lung 
and Blood Institute (NHBI) [20].
In the general population the prevalence of MS differs 
widely among ethnic groups and according to diagnostic 
criteria used [21-23]. De Varies et al showed that the 
prevalence of MS among renal transplant patients using 
the original NCEP ATP III criteria was 63% [7]. The 
Australian study on renal transplant patients using the 
same criteria revealed 50% prevalence of MS among 
these patients [24]. Porrini et al found that 37.7% of 
Spanish RTRs had MS by using the modified criteria 
[17]. These reports suggested that MS is more prevalent 
in renal transplant recipients as compared to the general 
population with ethnic variation. 
Obesity is common in renal transplant recipients and is 
associated with worsening cardiovascular parameters and 
proteinuria progression [24]. The metabolic syndrome is 
a prominent risk factor for new-onset diabetes mellitus 
[17]. It has been reported that MS is a risk factor for 
renal dysfunction in the general population [15] and a 
prominent risk factor for chronic graft dysfunction [7, 17, 
25, 26]. Our study did not show significant difference 
in serum creatinine levels between MS and non-MS 
patients.
Our results showed that the prevalence of MS differed 
according to the criteria used; it is slightly lower by 
using the IDF than the NCEP ATP III criteria (25.3% 
versus 28.6%). By using the NCEP ATP III criteria the 
prevalence of MS in our patients is consistent with the 
results of Ozdemir et al [25]. Some studies reported 
higher prevalence [7, 27, 28] while other investigators 
showed less prevalence [26, 29, 30] compared to our 
results. This may be due to ethnic variations. MS in this 
study was more prevalent in females compared to males, 
which is consistent with the results shown by the Chinese 
study [31] and by Elahi et al [27]. In contrast, the results 
of the Japanese study [30] showed that the prevalence 
of MS was more common in males than females. The 
most common component of metabolic syndrome was 
high blood pressure which is similar to the results of the 
Chinese study [31] and Elahi et al [27]. The least common 
component was impaired fasting glucose and diabetes 
mellitus which is consistent with the results shown by 
Elahi et al [27]. On other hand, the Chinese study results 
[31] showed that low high density lipoprotein-cholesterol 
level was the least common component. 
Conclusion
The prevalence of MS in our renal transplant patients is 
high, affecting females more than males.
References
1. Reaven GM: Role of insulin resistance in human 
disease. Diabetes. 1988; 37: 1595–1607. 
2. National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults (Adult Treatment Panel 
III): Third Report of the National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III) final report. Circulation. 
2002;106: 3143–421. 
3. McKeown NM, Meigs JB, Liu S, Saltzman E, 
Wilson PW, Jacques PF. Carbohydrate nutrition, insulin 
resistance, and the prevalence of the metabolic syndrome 
in the Framingham Offspring Cohort. Diabetes Care. 
2004;27: 538–46. 
4. Panagiotakos DB, Pitsavos C, Chrysohoou C, 
Skoumas J, Tousoulis D, Toutouza M, Toutouzas P, 
Stefanadis C. Impact of lifestyle habits on the prevalence 
of the metabolic syndrome among Greek adults from the 
ATTICA study. Am Heart J. 2004;147: 106–12.
5. Lakka TA, Laaksonen DE, Lakka HM, Männikkö 
N, Niskanen LK, Rauramaa R, Salonen JT. Sedentary 
lifestyle, poor cardiorespiratory fitness and the metabolic 
syndrome. Med Sci Sports Exerc. 2003;35: 1279–86.
6. Ford ES, Giles WH, Mokdad AH. Increasing prevalence 
of the metabolic syndrome among U.S. Adults. Diabetes 
Care. 2004;27(10): 2444-9.
7. de Vries AP, Bakker SJ, van Son WJ, van der Heide 
JJ, Ploeg RJ, The HT, de Jong PE, Gans RO. Metabolic 
syndrome is associated with impaired long term renal 
                                                          Total (n = 91)                                          Men (n = 56)                        Women (n = 35)
Central obesity                                 46                                                       36                                         63
Hypertension                                58                                                    60                                         54
High TG                                                44                                                    48                                         37
Low HDL-Cholesterol                          33                                                    25                                         46
Hyperglycemia                               29                                                    34                                         23
MS (NCEP-ATP III criteria)               28.6                                                    25                                         34.2 
MS (IDF criteria)                               25.3                                                   30.4                                               21.4 
Table 1: Prevalence of different components of the metabolic syndrome in the study population
TG: triglyceride; HDL: high density lipoprotein; MS: metabolic syndrome; NCEP-ATP: National Cholesterol Education Program Adult Treatment 
Panel III; IDF: International Diabetes Federation
144
Arab Journal of Nephrology and Transplantation
Elkehili, Kekli and Grera  
allograft function; not all component criteria contribute 
equally. Am J Transplant. 2004; 4(10): 1675-83.
8. Galassi A, Reynolds K, He J. Metabolic syndrome 
and risk of cardiovascular disease: a meta-analysis. Am J 
Med. 2006;119: 812-19.
9. Mottillo S, Filion KB, Genest J, Joseph L, Pilote 
L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. 
The Metabolic Syndrome and Cardiovascular Risk 
A Systematic Review and Meta-Analysis.  J Am Coll 
Cardiol. 2010;56:1113-32.
10. Arend SM, Mallat MJ, Westendorp RJ, van der 
Woude FJ, van Es LA. Patient survival after renal 
transplantation; more than 25 years follow-up. Nephrol 
Dial Transplant 1997;12: 1672−9. 
11. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, 
Persson NH, Lundgren G. Ischemic heart disease−major 
cause of death and graft loss after renal transplantation in 
Scandinavia. Transplantation 1995;60: 451−7. 
12. Foley RN, Parfrey PS. Sarnak MJ. Epidemiology of 
cardiovascular disease in chronic renal disease. J Am Soc 
Nephrol 1998;9 Suppl 12: S16−23. 
13. Ojo AO, Hanson JA, Wolfe RA, Leichtman AS, 
Agodoa LY, Port FK. Long-term survival in renal 
transplant recipients with graft function. Kidney Int 
2000;57: 307−13.
14. van Dijk PC, Jager KJ, de Charro F, Collart F, 
Cornet R, Dekker FW, Grönhagen-Riska C, Kramar R, 
Leivestad T, Simpson K, Briggs JD. Renal replacement 
therapy in Europe: The results of a collaborative effort 
by the ERA−EDTA registry and six national or regional 
registries. Nephrol Dial Transplant 2001;16(6): 1120-29.
15. Fox CS, Larson MG, Leip EP, Culleton B, Wilson 
PW, Levy D. Predictors of new-onset kidney disease in a 
community based population. JAMA 2004;291: 844-50.
16. El-Atat FA, Stas SN, McFarlane SI, Sowers JR. The 
relationship between hyperinsulinemia, hypertension, and 
progressive renal disease. J Am Soc Nephrol 2004;15: 
2816-27.
17. Porrini E, Delgado P, Bigo C, Alvarez A, Cobo M, 
Checa MD, Hortal L, Fernández A, García JJ, Velázquez 
S, Hernández D, Salido E, Torres A. Impact of metabolic 
syndrome on graft function and survival after cadaveric 
renal transplantation. Am J Kidney Dis 2006;48(1): 
134-42.
18. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC 
Jr, Lenfant C. American Heart Association; National 
Heart, Lung, and Blood Institute. Definition of metabolic 
syndrome: Report of the National Heart, Lung and 
Blood Institute/American Heart Association conference 
on scientific issues related to definition. Circulation 
2004;109: 433-8.
19. Alberti KG, Zimmet P, Shaw J. IDF Epidemiological 
Task Force Consensus Group. The metabolic syndrome - 
a new worldwide definition. Lancet 2005;366: 1059-62.
20. Grundy SM, Cleeman JI, Daniels SR, Donato KA, 
Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage 
PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and 
management of the metabolic syndrome: an American 
Heart Association/National Heart, Lung, and Blood 
Institute Scientific Statement. Circulation. 2005;112: 
2735–52.
21. Morales DD, Punzalan FE, Paz-Pacheco E, Sy RG, 
Duante CA. Metabolic syndrome in the Philippine general 
population: prevalence and risk for atherosclerotic 
cardiovascular disease and diabetes mellitus. Diab Vasc 
Dis Res. 2008 Mar;5(1):36-43.
22. Ford ES, Giles WH, Dietz WH. Prevalence of the 
metabolic syndrome among US adults: Findings from the 
third National Health and Nutrition Examination Survey. 
JAMA. 2002;287: 356–9.
23. Al-Nozha M, Al-Khadra A, Arafah MR, Al-Maatouq 
MA, Khalil MZ, Khan NB, Al-Mazrou YY, Al-Marzouki 
K, Al-Harthi SS, Abdullah M, Al-Shahid MS, Al-
Mobeireek A, Nouh MS. Metabolic syndrome in Saudi 
Arabia. Saudi Med J. 2005 Dec;26(12):1918-25.
24. Armstrong KA, Campbell SB, Hawley CM, Nicol 
DL, Johson DW, Isbel NM. Obesity is associated with 
worsening cardiovascular risk factor profiles and 
proteinuria progression in renal transplant recipients. Am 
J Transplant 2005;5: 2710-18.
25. Ozdemir FN, Karakan S, Akgul A, Haberal M. 
Metabolic syndrome is related to long-term graft function 
in renal transplant recipients. Transplant Proc. 2009 Sep; 
41(7):2808-10.
26. Faenza A, Fuga G, Nardo B, Donati G, Cianciolo G, 
Scolari MP, Stefoni S. Metabolic syndrome after kidney 
transplantation. Transplant Proc. 2007 Jul-Aug;39 
(6):1843-46.
27. Elahi T, Akhtar F, Ahmed E, Naqvi R. Prevalence 
of metabolic syndrome in renal transplant recipients-a 
single centre experience. J Pak Med Assoc. 2009 Aug;59 
(8): 533-36.
28). Luan FL, Stuckey LJ, Ojo AO. Abnormal glucose 
metabolism and metabolic syndrome in non-diabetic 
kidney transplant recipients early after transplantation. 
Transplantation. 2010 Apr 27;89 (8):1034-9.
29. Kishikawa H, Nishimura K, Kato T, Kobayashi 
Y, Arichi N, Okuno A, Fujii N, Kyo M, Takahara S, 
Ichikawa Y.  Prevalence of the metabolic syndrome in 
kidney transplantation. Transplant Proc. 2009 Jan-Feb; 
41(1):181-3.
30. Naganuma T, Uchida J, Kinoshita Y, Kuroki Y, 
Takemoto Y, Yoshimura R, Sugimura K, Nakatani T. 
The prevalence of metabolic syndrome in Japanese renal 
transplant recipients. Nephrology (Carlton) 2007; 12: 
413-17.
31. Cheung CY, Chan HW, Liu YL, Chan YH, Wong 
HS, Chak WL, Choi KS, Chau KF, Li CS. Prevalence 
of metabolic syndrome in Chinese renal transplant 
recipients. HKMJ. 2008; 14(5):379-84.
